Amgen Stock Continues to Rise Following Court Ruling
Amgen stock (NASDAQ:AMGN) continued its positive run today, gaining 4.9% after the judge upheld two of the firm’s key patents. On Friday, a New Jersey judge ruled in Amgen’s favor in a dispute with Novartis (NYSE:NVS) ... [Read]
BMY Stock Drops 7% After Delaying Acquisition of Celgene Corporation
Similar to cannabis stocks, Bristol-Myers Squibb (NYSE:BMY) has not had a solid start to the week, and neither has Celgene Corporation (NASDAQ:CELG). These two, however, have something to do with one another. On news that ... [Read]
BHC Stock Closes Up 9%: Bausch 2019 Outlook Increased After Successful Q1
On Monday, May 6, BHC stock jumped nearly 10% after Bausch Health Companies (TSX:BHC) announced its Q1 2019 results and increased its 2019 outlook. Here’s what we know. BHC Stock Up On Bausch Earnings Formerly ... [Read]
US Drug Companies Raise Med Prices Despite President Trump Pressure
2019 is not kicking off to a great start for most Americans. US drug companies kicked off the year implementing price increases on more than 250 prescription drugs—despite pressure from President Trump to not do ... [Read]
Johnson & Johnson Shares Nosedive After New Asbestos Report Surfaces
The Johnson & Johnson (NYSE:JNJ) asbestos saga continues. This morning, Reuters released a “special report” documenting that the manufacturer knew that its most popular product contained asbestos. Due to this report, JNJ shares have plummeted as ... [Read]
Johnson & Johnson Baby Powder Cancer Case Cleared
Johnson & Johnson (NYSE:JNJ) has successfully persuaded a California jury to reject a woman’s claims that asbestos in the company’s well-known baby powder is what caused her to develop cancer. Johnson & Johnson’s baby powder ... [Read]
Pfizer Offers Early Retirement Ahead of Layoffs Next Year
Pfizer Inc. (NYSE:PFE) has been a long-time heavy hitter in the pharmaceutical industry, but it is soon facing layoffs. According to reports by CNBC, Pfizer is offering early retirement to US workers ahead of its ... [Read]
Teva Pharmaceutical Gaining Momentum After FDA Approves EpiPen
On Thursday, the FDA approved the Teva EpiPen, a move that marks a significant blow to the company’s rival, Mylan N.V. To no surprise, the market is still riding this high on Friday, allowing the ... [Read]
Johnson & Johnson’s Robust Growth Signifies Potential Increase in Shareholders Returns?
Johnson & Johnson (NYSE:JNJ) continues accelerating its revenue base through innovations and portfolio diversification. Second-quarter Johnson & Johnson revenue increased at a double-digit rate year over year, driven by a stable performance from Medical Devices ... [Read]
Is the Dip in Johnson & Johnson Shares Offering a Buying Opportunity?
Johnson & Johnson shares tumbled more than 17% since it hit the all-time high of $148 a share at the beginning of the year. Its share price has been under pressure over the last couple ... [Read]